Mass Tort Case Acquisition Cost: What Plaintiff Firms Need to Know in 2026

Why Mass Tort Case Acquisition Cost Is the Number That Actually Runs Your Firm

Mass tort case acquisition cost is the single most consequential line item in a plaintiff firm's docket economics, directly determining whether a litigation investment generates margin or destroys it. As several major MDLs approach resolution cycles in 2026 and new tort inventories come to market, the spread between acquisition cost and projected case value has compressed in ways that punish firms operating without clear benchmarks. Understanding this number, across every funnel stage, is now a competitive requirement.

This post breaks down how to think about acquisition cost the right way, what the real benchmarks look like across tort types, and where most firms lose money without realizing it.

What Mass Tort Case Acquisition Cost Actually Means

The term sounds simple but it collapses three distinct cost units that mean very different things to your bottom line.

The first is cost per qualified lead (CPQL). This is what you pay to get a lead through your door that meets basic eligibility criteria: right product, right injury type, right timeframe. Raw leads are cheaper and nearly worthless as a planning metric. Qualified leads are the starting point for real math.

The second is media CPA, or cost per acquisition at the signed retainer stage. This is what you paid in media and agency fees to convert a qualified lead into a client with a signed contract. This number is where most firms focus, and it matters, but it still is not the whole picture.

The third is cost per kept case (CPK). This is the one that actually ties to your P&L. CPK accounts for cases that fall out after signing: clients who become unreachable, cases that fail additional medical screening, duplicates, and disqualified claimants that slipped through initial intake. CPK is calculated by dividing your total campaign spend by the number of cases that survive all screening and remain active in the litigation. On a poorly managed campaign, CPK can be 40 to 60 percent higher than your media CPA. That gap is profit walking out the door.

Understanding mass tort case acquisition cost means tracking all three, not just the number your lead vendor quotes you.

Realistic Benchmarks Across Tort Types

Numbers vary significantly depending on the tort, the media channel, and where the MDL sits in its lifecycle. That said, here are realistic ranges based on current market conditions.

For major pharmaceutical and medical device torts with active MDLs, qualified lead costs typically run between $150 and $400. Signed retainer costs (media CPA) range from $800 to $2,500 depending on conversion efficiency and tort complexity. CPK, once you account for attrition, often lands between $1,200 and $3,500.

For hot torts in early formation, where media inventory is less competitive and claimant pools are large, you can see CPQL as low as $80 to $150. But early-stage torts carry more uncertainty on settlement value and timeline, so lower acquisition cost does not automatically mean better ROI.

For legacy torts near resolution, media CPA often spikes because available claimant pools shrink while firms compete harder for the remaining inventory. You may pay $3,000 to $5,000 per signed case in a mature tort, which only makes sense if expected settlement value is strong and the MDL timeline is predictable.

Tracking these benchmarks in real time is part of what separates firms that run disciplined campaigns from those that rely on gut feel. Referencing a hot tort report or watching what other firms are spending through sources like Kantar media data gives you a market signal worth paying attention to.

How Conversion Rates Move Your Total Acquisition Cost

Your lead-to-signed-case conversion rate is the multiplier that sits underneath every acquisition cost calculation. A firm converting 20 percent of qualified leads to signed retainers has a very different CPK than a firm converting 35 percent, even if both paid identical CPQLs.

Consider a simple model. Two firms both pay $200 per qualified lead. Firm A converts 20 percent, so they spend $1,000 in lead cost per signed case before adding overhead and intake costs. Firm B converts 35 percent and spends $571 per signed case in lead cost. Run that across 500 cases and Firm B has kept over $200,000 more in margin before a single settlement check arrives.

The driver of that gap is almost always intake. Response time, screener quality, and follow-up persistence account for more of the conversion spread than most firms acknowledge. Research consistently shows that a two-hour delay in first callback response can reduce conversion rates by 25 percent or more. In practical terms, that means your effective CPK climbs sharply not because your media costs went up, but because your intake operation let leads go cold. A firm investing in faster intake response, whether through trained staff, AI-assisted triage, or 24/7 answering services, is directly lowering its mass tort case acquisition cost without touching its media budget. For firms exploring AI-assisted intake tools, the economics here are concrete enough to justify serious evaluation.

Third-Party Litigation Financing and the Acquisition Cost Equation

One topic that rarely gets connected to per-case cost math is third-party litigation funding (TPLF). Plaintiff firms building large case inventories in pre-settlement MDLs often carry significant capital out the door for months or years before resolution. That capital has a cost, whether it is opportunity cost, line-of-credit interest, or the discount rate on a litigation finance arrangement.

When you model mass tort case acquisition cost properly, the financing structure matters. A firm borrowing at eight percent annually to fund a 36-month campaign on a tort that settles at month 30 has a very different effective cost per case than the media spend alone suggests. Litigation funders who specialize in mass tort portfolios often underwrite against expected settlement value by tort type, which means the better your case quality and CPK discipline, the better the terms you can negotiate.

Firms that treat TPLF as a last resort are leaving leverage on the table. Firms that build it into their acquisition cost model from the start can take on larger case volumes with less internal capital strain. The math is not complicated, but it requires treating acquisition cost as a total-cost-of-capital problem, not just a media spend problem.

What Separates Campaigns That Work From Ones That Drain Budget

Execution separates firms that build profitable mass tort client intake processes from those that accumulate expensive, low-quality case inventories. A few principles hold across nearly every tort type.

• Screen early and screen hard. Loose initial qualification criteria lower your CPQL on paper but inflate your CPK in reality. Build specific criteria into your intake scripts and stick to them, even when volume pressure makes it tempting to loosen standards.
• Track CPK, not just media CPA. If your reporting only goes to signed retainer, you are flying blind on your actual return. Build a tracking system that follows cases through secondary screening and medical record review.
• Respond fast. This bears repeating because the data on intake response time is unambiguous. Every hour of delay costs you conversion rate points and raises your effective acquisition cost. Staff and technology investments that cut response time pay for themselves quickly.
• Match media channel to tort type and MDL stage. Facebook and digital video work well for broad awareness on large claimant pools. Targeted search works well for torts with high consumer awareness. Mixing channels without a clear rationale wastes spend.
• Model ROI by tort type before committing budget. A $1,500 CPK on a tort with an expected individual settlement of $60,000 and a 33 percent contingency fee looks very different from a $1,500 CPK on a tort with uncertain settlement value and a five-year timeline. Portfolio-level modeling, across multiple torts simultaneously, lets you allocate capital where the risk-adjusted return is best.

Pitfalls: Bar Rules, TCPA, and Wasted Spend

Compliance is not optional and it affects your cost structure directly. TCPA and CIPA exposure from auto-dialed or pre-recorded outreach to leads has generated real litigation against plaintiff firms and lead vendors. If your intake operation uses technology that triggers TCPA liability, the cost of that exposure needs to be factored into your true acquisition cost.

State bar advertising rules add another layer. Many states require specific disclosures on mass tort advertising, and attorney supervision requirements vary. Campaigns that run afoul of bar rules create remediation costs, potential disciplinary exposure, and, in some cases, contract voidability issues with signed clients. Review your state-specific rules before launching any mass tort lead generation campaign.

Wasted spend is the quieter killer. Buying leads from vendors who recycle or resell the same claimant pool across multiple firms inflates your apparent lead volume while tanking conversion rates. Requiring exclusivity or near-exclusivity on purchased leads, and auditing lead source quality regularly, is basic hygiene that many firms skip until they have already wasted significant budget.

How MTAA Approaches This

At Mass Tort Ad Agency, we have managed over $250 million in Facebook ad spend for more than 600 plaintiff law firms across more than 100 torts. The pricing model is transparent: ad spend plus a 15 percent management fee, no markup on media, no hidden costs. That structure matters because it aligns our incentives with yours. We make more when your spend grows because results justify it, not because we marked up your media costs.

What we bring is pattern recognition across a large enough sample of firms and tort types to benchmark your CPK against real market data, flag intake inefficiencies that are silently inflating your acquisition cost, and help model campaign investment against expected MDL outcomes. For firms thinking about AI integration into intake and operations, we have seen firsthand how the right tools cut response time and improve conversion rates in ways that move the CPK number meaningfully.

The Bottom Line on Mass Tort Case Acquisition Cost

Mass tort case acquisition cost is not a single number. It is a system that connects media spend, intake performance, case attrition, financing structure, and MDL economics into a coherent picture of what you are actually paying to build your docket. Firms that model it carefully, benchmark against real market data, and execute intake with discipline consistently outperform firms that focus only on the media buy. If you are evaluating where to put capital in the current tort environment, start with a clear-eyed look at your CPK by tort type. That number will tell you more about the health of your practice than almost anything else on your balance sheet.